Related references
Note: Only part of the references are listed.Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis
Simina Ticau et al.
NEUROLOGY (2021)
Does protein aggregation drive postmitotic tissue degeneration?
Jeffery W. Kelly
SCIENCE TRANSLATIONAL MEDICINE (2021)
Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis
Mahima Kapoor et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2019)
Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis
Matthias Schmidt et al.
NATURE COMMUNICATIONS (2019)
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials
Joel N. Buxbaum
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Predictive model of response to tafamidis in hereditary ATTR polyneuropathy
Ceclia Monteiro et al.
JCI INSIGHT (2019)
Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis
Ana Martins da Silva et al.
JOURNAL OF NEUROLOGY (2018)
Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin
Jacquelyn L. S. Hanson et al.
CIRCULATION-HEART FAILURE (2018)
Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
Hartmut H. Schmidt et al.
MUSCLE & NERVE (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Oligonucleotide Drugs for Transthyretin Amyloidosis
Joel N. Buxbaum
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy
Teresa Coelho et al.
NEUROLOGY (2018)
Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
Andrea Cortese et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Sural nerve injury in familial amyloid polyneuropathy MR neurography vs clinicopathologic tools
Jennifer Kollmer et al.
NEUROLOGY (2017)
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Joseph D. Schonhoft et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Cognitive impairment in liver transplanted patients with transthyretin-related hereditary amyloid polyneuropathy
Vanda Freitas Castro et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Cutaneous Nerve Biomarkers in Transthyretin Familial Amyloid Polyneuropathy
Gigi J. Ebenezer et al.
ANNALS OF NEUROLOGY (2017)
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
Marcia Waddington Cruz et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis
Yoshiki Sekijima et al.
NEUROLOGY (2016)
Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
D. Adams et al.
REVUE NEUROLOGIQUE (2016)
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures
Sunil M. Kurian et al.
THERANOSTICS (2016)
Liver Transplantation in Transthyretin Amyloidosis: Issues and Challenges
Andreia Carvalho et al.
LIVER TRANSPLANTATION (2015)
Targeting protein aggregation for the treatment of degenerative diseases
Yvonne S. Eisele et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo-Goran Ericzon et al.
TRANSPLANTATION (2015)
Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States
Yves Ingenbleek et al.
ADVANCES IN NUTRITION (2015)
In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography
Jennifer Kollmer et al.
BRAIN (2015)
CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings
Luis F. Maia et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho et al.
JOURNAL OF NEUROLOGY (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Christine E. Bulawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Atomic View of a Toxic Amyloid Small Oligomer
Arthur Laganowsky et al.
SCIENCE (2012)
Liver Transplantation for Familial Amyloidotic Polyneuropathy: Impact on Swedish Patients' Survival
Sadahisa Okamoto et al.
LIVER TRANSPLANTATION (2009)
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
Yoshiki Sekijima et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2006)
The biological and chemical basis for tissue-selective amyloid disease
Y Sekijima et al.
CELL (2005)
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture
N Reixach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Sequence-dependent denaturation energetics:: A major determinant in amyloid disease diversity
P Hammarström et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Trans-suppression of misfolding in an amyloid disease
P Hammarström et al.
SCIENCE (2001)
An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured
X Jiang et al.
BIOCHEMISTRY (2001)
Share Paper
